# Integrated Proteomics and Metabolomics Reveal the Direct Hepatic Protection of Propionate Against Alcoholic Liver Disease via the RGN-PPARα Pathway

**Authors:** Haidi Wang, Haitao Liu, Miaoxin Wang, Tengjiao Chi, Fengting Liu, Xinyan Qu, Yan Mu, Qi Xu, Quanbo Wang

PMC · DOI: 10.3390/nu18050872 · Nutrients · 2026-03-09

## TL;DR

This study shows that propionate protects the liver from alcohol damage by activating a specific pathway involving RGN and PPARα, independent of gut effects.

## Contribution

The paper reveals a direct liver-protective mechanism of propionate against ALD via the RGN-PPARα pathway.

## Key findings

- Propionate reduces liver fat and oxidative stress in an acute ALD model.
- Propionate activates lipolysis and fatty acid oxidation through RGN and PPARα.
- Propionate enhances antioxidant defenses and restores lipid balance in ALD.

## Abstract

Background: Propionate, a gut microbiota-derived metabolite, has previously been shown to alleviate chronic alcoholic liver disease (ALD) by preserving intestinal barrier integrity. However, its direct hepatoprotective mechanisms remain unclear. Methods: In this study, employing an acute ALD model to minimize the interference from gut–liver axis effects, we investigated the direct hepatic protection of propionate. Results: Our results demonstrated that propionate administration significantly attenuated hepatic steatosis and oxidative stress. Consistently, in EtOH/OA (oleic acid)-exposed AML-12 hepatocytes, propionate enhanced cell viability and reduced lipid accumulation. Integrated proteomic and metabolomic analyses revealed that propionate altered hepatic proteins and metabolites profiles to stimulate lipolysis, promote fatty acid oxidation, and strengthen antioxidant defenses, consequently restoring lipid homeostasis in ALD mice. Mechanistically, we identified that these beneficial effects may be driven by the upregulation of regucalcin (RGN) following propionate treatments, which, in turn, may activate downstream PPARα signaling via increased levels of p-AMPK, PPARα, ACOX1 and CPT1A. Conclusions: These findings provide novel insight into the liver-centric mechanism through which propionate ameliorates ALD and further support its therapeutic potential in ALD treatment.

## Linked entities

- **Genes:** RGN (regucalcin) [NCBI Gene 9104], PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465], ACOX1 (acyl-CoA oxidase 1) [NCBI Gene 51], CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374]
- **Chemicals:** propionate (PubChem CID 104745), oleic acid (PubChem CID 445639)
- **Diseases:** alcoholic liver disease (MONDO:0043693), ALD (MONDO:0010247)

## Full-text entities

- **Genes:** Rgn (regucalcin) [NCBI Gene 19733] {aka GNL, RC, SMP-30, SMP30}, Cpt1a (carnitine palmitoyltransferase 1a, liver) [NCBI Gene 12894] {aka C730027G07, CPTI, Cpt1}, Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Acox1 (acyl-Coenzyme A oxidase 1, palmitoyl) [NCBI Gene 11430] {aka AOX, Acox, D130055E20Rik, Paox}
- **Diseases:** hepatic steatosis (MESH:D005234), ALD (MESH:D008108)
- **Chemicals:** OA (MESH:D019319), Propionate (MESH:D011422), lipid (MESH:D008055), oleic acid (MESH:D019301), fatty acid (MESH:D005227), EtOH (MESH:D000431)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12987040/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12987040/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12987040/full.md

---
Source: https://tomesphere.com/paper/PMC12987040